trial,pubID,pseudogroup,weeks,group,IgD-/IgM-/IgA-/IgG+/Antigen++ B cells
G002,G002-611,2.0,8,4,1994.0
G002,G002-710,2.0,8,4,831.0
G002,G002-831,1.0,8,2,204.0
G002,G002-387,2.0,8,4,806.0
G002,G002-136,1.0,8,2,1137.0
G002,G002-365,2.0,8,4,888.0
G002,G002-145,1.0,8,2,523.0
G002,G002-396,2.0,8,4,1600.0
G002,G002-630,1.0,8,2,275.0
G002,G002-794,2.0,8,4,462.0
G002,G002-855,1.0,8,2,131.0
G002,G002-104,2.0,8,4,329.0
G002,G002-947,1.0,8,2,90.0
G002,G002-820,1.0,8,2,263.0
G002,G002-293,1.0,8,2,387.0
G002,G002-119,1.0,8,2,169.0
G002,G002-943,1.0,8,2,137.0
G002,G002-230,1.0,8,2,1134.0
G002,G002-957,1.0,8,2,172.0
G002,G002-577,1.0,8,2,276.0
G002,G002-480,1.0,8,2,35.0
G002,G002-341,1.0,8,2,141.0
G002,G002-493,1.0,8,2,19.0
G002,G002-620,1.0,8,2,22.0
